Van Dyk, KathleenZhou, XingtaoSmall, Brent J.Ahn, JaeilZhai, WantingAhles, TimGraham, DeenaJacobsen, Paul B.Jim, HeatherMcDonald, Brenna C.Nudelman Holohan, KellyPatel, Sunita K.Rebeck, G. WilliamRoot, James C.Saykin, Andrew J.Cohen, Harvey JayMandelblatt, Jeanne S.Carroll, Judith E.2022-07-062022-07-062021-01-27Van Dyk K, Zhou X, Small BJ, et al. Protective Effects of APOE ε2 Genotype on Cognition in Older Breast Cancer Survivors: The Thinking and Living With Cancer Study. JNCI Cancer Spectr. 2021;5(2):pkab013. Published 2021 Jan 27. doi:10.1093/jncics/pkab013https://hdl.handle.net/1805/29501Background: Cancer-related cognitive decline (CRCD) has been linked to apolipoprotein E (APOE) gene ε4 polymorphisms. APOE ε4 polymorphisms are also the strongest genetic risk for late-onset Alzheimer disease (AD), whereas ε2 polymorphisms protect against AD. However, the effects of ε2 polymorphisms on CRCD have not been evaluated. Methods: We evaluated nonmetastatic breast cancer survivors (n = 427) and matched noncancer controls (n = 407) ages 60-98 years assessed presystemic therapy from August 2010 to December 2017 with annual follow-up to 24 months. Neuropsychological assessment measured attention, processing speed, executive function, and learning and memory. Linear mixed-effects models tested the effects of having an ε2 allele (vs none) on longitudinal cognitive domain z scores by treatment group (chemotherapy with or without hormonal therapy, hormonal therapy, and control) controlling for covariates; participants with ε2/ε4 genotype were excluded. Sensitivity analyses examined effects of other covariates and any ε4 positivity. Results: There was an interaction with genotype for attention, processing speed, and executive functioning domain scores (Beta = 0.32, 95% confidence interval = 0.00 to 0.65); the chemotherapy group with an ε2 allele had higher scores at baseline and maintained higher scores over time compared with those without an ε2 allele, and this protective effect was not seen for other groups. There was no effect of ε2 on learning and memory domain scores. Conclusions: APOE ε2 polymorphisms may protect against CRCD in older breast cancer survivors receiving chemotherapy. With replication, this information could be useful for survivorship care and informing future studies of possible links to AD and defining mechanisms of protection.en-USAttribution 4.0 InternationalAlzheimer DiseaseBreast NeoplasmsCognitive DysfunctionExecutive FunctionArticle